Please use this identifier to cite or link to this item:
|Title:||Metabolomics in Toxicology and Preclinical Research|
|Authors:||RAMIREZ Tzutzuy; DANESHIAN Mardas; KAMP Hennicke; BOIS Frederic; CLENCH Malcolm R.; COEN Muireann; DONLEY Beth; FISCHER Steven M.; EKMAN Drew R.; FABIAN Eric; GUILLOU Claude; HEUER Joachim; HOGBERG Helena T.; JUNGNICKEL Harald; KEUN Hector C.; KRENNRICH Gerhard; KRUPP Eckart; LUCH Andreas; NOOR Fozia; PETER Erik; RIEFKE Bjoern; SEYMOUR Mark; SKINNER N.; SMIRNOVA Lena; VERHEIJ Elwin; WAGNER Silvia; HARTUNG Thomas; VAN RAVENZWAAY Bennard; LEIST Marcel|
|Citation:||ALTEX-ALTERNATIVES TO ANIMAL EXPERIMENTATION vol. 30 no. 2 p. 209-225|
|Publisher:||SPEKTRUM AKADEMISCHER VERLAG-SPRINGER-VERLAG GMBH|
|Type:||Articles in periodicals and books|
|Abstract:||Metabolomics, the comprehensive analysis of metabolites in a biological system, provides detailed information about the biochemical/physiological status of a biological system, and about the changes caused by chemicals. Metabolomics analysis is used in many fields, ranging from the analysis of the physiological status of genetically modified organisms in safety science to the evaluation of human health conditions. In toxicology, metabolomics is the -omics discipline that is most closely related to classical knowledge of disturbed biochemical pathways. It allows rapid identification of the potential targets of a hazardous compound. It can give information on target organs and often can help to improve our understanding regarding the mode-of-action of a given compound. Such insights aid the discovery of biomarkers that either indicate pathophysiological conditions or help the monitoring of the efficacy of drug therapies. The first toxicological applications of metabolomics were for mechanistic research, but different ways to use the technology in a regulatory context are being explored. Ideally, further progress in that direction will position the metabolomics approach to address the challenges of toxicology of the 21st century. To address these issues, scientists from academia, industry, and regulatory bodies came together in a workshop to discuss the current status of applied metabolomics and its potential in the safety assessment of compounds. We report here on the conclusions of three working groups addressing questions regarding 1) metabolomics for in vitro studies 2) the appropriate use of metabolomics in systems toxicology, and 3) use of metabolomics in a regulatory context|
|JRC Directorate:||Institute for Health and Consumer Protection Historical Collection|
Files in This Item:
There are no files associated with this item.
Items in repository are protected by copyright, with all rights reserved, unless otherwise indicated.